NCT07169214
Evaluation of Safety, Efficacy, and Pharmacokinetics of BT-114143 Injection in Patients With Abnormal Uterine Bleeding
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Sep 23, 2025 to Apr 28, 2026 Show 5 more changesShow less
- Eligibility criteria expanded, about 34 words
- Trial completed
- Study completion date changed from estimate of Dec 31, 2025 to Apr 28, 2026
- Secondary endpoints: details revised at 2 of 8 entries
- Site details revised
- Minor Enrollment target: 36 to 39
- Primary completion date changed from estimate of Oct 31, 2025 to Sep 23, 2025
- Minor Secondary endpoints: details revised at 2 of 8 entriesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
safety evaluation
Timeframe: from the first administration to 2 weeks after the last administration
Secondary (8)
Change of menstrual bleeding volume from baseline
Percentage change of menstrual bleeding volume from baseline
The difference in the number of menstrual bleeding days between the post-treatment period and the baseline period in subjects.
The proportion of subjects with menstrual blood loss ≤ 80 ml after treatment.
The proportion of subjects with a reduction in menstrual blood loss of ≥50 ml after treatment compared with the baseline
Show 3 moreShow less
The proportion of subjects with a reduction in menstrual blood loss of ≥36 ml after treatment compared with the baseline.
The change in the Menorrhagia Impact Questionnaire (MIQ) score from baseline after treatment in subjects.
The change in the Menstrual Discomfort Questionnaire (MDQ) score from baseline after treatment in subjects.
Arms and interventions
low-dose groupExperimental
Subjects received low-dose BT-114143 Injection treatment
Medium-dose groupExperimental
Subjects received Medium-dose BT-114143 Injection treatment
High-dose GroupExperimental
Subjects received High-dose BT-114143 Injection treatment
control groupPlacebo comparator
The subjects receive normal saline treatment.
Drugs: BT-114143 Injection at low dose, BT-114143 Injection at Medium-dose, BT-114143 Injection at High-dose, control group
Sites
1 site in 1 country
- Peking Union Medical College HospitalBeijing, Beijing Municipality, China